Piramal Pharma: Should You Buy, Hold, or Sell Right Now?
- September 3, 2026
- Posted by: Kunal Singla
- Category: Market
Piramal Pharma share price Rs 212.96 (NSE), near its 52-week high. 52-week range Rs 132.30 to Rs 220.36. Q1 FY27 net loss narrowed to Rs 69.39 crore from Rs 81.7 crore YoY.
Quick Answer
Piramal Pharma Ltd share price is trading around Rs 213, close to its 52-week high of Rs 220.36 and well above its 52-week low of Rs 132.30. Q1 FY27 revenue grew 18.4 percent year on year to Rs 2,359.33 crore, with the net loss narrowing to Rs 69.39 crore from Rs 81.7 crore a year earlier, though the company remains loss-making across its CDMO, complex hospital generics and consumer healthcare businesses. Because Piramal Pharma continues to report losses, standard valuation ratios like PE are not meaningful. Investors focused on the narrowing loss trend and revenue growth may see the stock’s proximity to its highs as reasonable, while others may want to see the company reach sustained profitability first.
Piramal Pharma share price is trading close to its 52-week high of Rs 220.36, with Piramal Pharma share price near Rs 213 on the NSE, well above its 52-week low of Rs 132.30. With losses narrowing alongside continued revenue growth in Q1 FY27, investors are asking whether this diversified pharma company is a stock to buy near its highs, a hold, or a sell given it remains loss-making.
This Piramal Pharma stock analysis walks through the Q1 FY27 numbers, valuation considerations for a loss-making company, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Piramal Pharma
Keep this backdrop in mind when reading the rest of this Piramal Pharma share price review. Before deciding on Piramal Pharma share price, it helps to understand the underlying business. Piramal Pharma Ltd. operates across three main businesses: contract development and manufacturing (CDMO) services for global pharmaceutical clients, complex hospital generics including inhalation anaesthesia and injectables, and an India consumer healthcare business selling over-the-counter wellness products.
This diversified structure means Piramal Pharma’s consolidated results reflect performance across quite different business models, with the CDMO and complex generics businesses requiring significant ongoing investment while the consumer healthcare business follows more typical FMCG dynamics.
Piramal Pharma Share Price Today: Key Levels
The table below summarises where Piramal Pharma share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Piramal Pharma CMP (NSE) | Rs 212.96 |
| Piramal Pharma CMP (BSE) | Rs 213.00 |
| 52-Week High | Rs 220.36 |
| 52-Week Low | Rs 132.30 |
| Market Capitalisation | Approximately Rs 28,444 crore |
| NSE Volume (latest session) | 6,60,343 shares |
Piramal Pharma share price is trading close to its 52-week high, reflecting investor optimism around the company’s narrowing losses and continued revenue growth, even as the business has not yet reached overall profitability.
Check the Univest Screener for Live Stock Data
Piramal Pharma Financial Performance
Track this line item closely if you are following Piramal Pharma share price closely. The Piramal Pharma share price trend is closely tied to how these numbers evolve each quarter. Piramal Pharma reported Q1 FY27 (June 2026 quarter) revenue of Rs 2,359.33 crore, up 18.4 percent year on year from Rs 1,992.11 crore, with the net loss narrowing to Rs 69.39 crore from Rs 81.7 crore in the same quarter a year earlier. This continued a broadly improving, though still loss-making, trend across recent quarters.
For the full year FY26, the company reported revenue of Rs 9,082.38 crore, down slightly from Rs 9,285.99 crore in FY25, with a net loss of Rs 325.94 crore, a reversal from a net profit of Rs 91.13 crore in FY25, showing the path to consistent profitability has not yet been a smooth one for this diversified pharma company.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 2,359.33 crore | Net loss Rs 69.39 crore | +18.4% revenue YoY, loss narrowed from Rs 81.7 crore YoY |
| FY26 (full year) | Rs 9,082.38 crore | Net loss Rs 325.94 crore | Reversed from Rs 91.13 crore profit in FY25 |
Valuation Check: Is Piramal Pharma Share Price Expensive?
It is one of the clearest signals available on Piramal Pharma share price today. Any view on Piramal Pharma share price should start from these valuation multiples. Because Piramal Pharma continues to report net losses, with a negative trailing EPS of Rs -2.36, the price to earnings ratio is not meaningful here. Return on equity stands at negative 3.58 percent, reflecting the company’s ongoing path back toward profitability.
The price to book ratio stands near 3.5 times, a relatively rich multiple for a currently loss-making company, suggesting the market continues to price in the long-term value of Piramal Pharma’s CDMO capabilities and consumer healthcare brands despite the near-term losses across its complex generics and CDMO segments.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Piramal Pharma share price. Piramal Pharma share price is currently positioned just below its 52-week high of Rs 220.36 and roughly 61 percent above its 52-week low of Rs 132.30, reflecting a strong overall run over the past year despite the company remaining loss-making. A stock trading this close to its high while still posting losses typically reflects the market rewarding the narrowing loss trend and revenue growth as evidence of an improving trajectory.
Trading volumes remain heavy, so investors should track Piramal Pharma share price alongside progress toward overall profitability across its various business segments, rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Piramal Pharma’s live price and technical levels.
Shareholding Pattern
Shifts here can influence Piramal Pharma share price more than headline news on some sessions. Piramal Pharma is part of the Piramal Group, one of India’s established diversified business conglomerates. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Piramal Pharma
- Narrowing losses: The net loss narrowed to Rs 69.39 crore in Q1 FY27 from Rs 81.7 crore a year earlier, suggesting incremental progress toward profitability.
- Continued revenue growth: Q1 FY27 revenue grew 18.4 percent year on year, showing healthy demand across the company’s CDMO, complex generics and consumer healthcare businesses.
- Diversified business portfolio: Exposure across CDMO services, complex hospital generics and consumer healthcare provides diversification, even as it adds complexity to assessing consolidated performance.
- Piramal Group backing: Being part of the established Piramal Group provides institutional and strategic support.
Risks and Factors to Watch
- Continued net losses: Despite the narrowing trend, Piramal Pharma remains loss-making at the consolidated level, and a full return to sustained profitability has not yet been achieved.
- Reversal from FY25 profitability: Full-year FY26 saw a reversal to a net loss from a profit in FY25, showing the path to consistent profitability has not been smooth.
- Complexity of diversified segments: Assessing Piramal Pharma’s consolidated performance requires understanding trends across quite different business models spanning CDMO, complex generics and consumer healthcare.
- Rich valuation for a loss-making company: A 3.5 times price to book ratio for a currently loss-making business assumes continued improvement, leaving room for disappointment if the narrowing loss trend does not continue.
Piramal Pharma Share Price Target: What the Data Suggests
Until then, Piramal Pharma share price remains best tracked through live, verified data rather than a single fixed number. Given Piramal Pharma’s continued net losses, conventional analyst price targets based on earnings multiples are not meaningful, and any published targets should be treated with some caution.
Investors considering this stock should track the Univest Screener for the latest quarterly disclosures on the company’s progress toward profitability, and should consult a SEBI-registered investment adviser given the elevated uncertainty in this stock.
Piramal Pharma: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Piramal Pharma share price right now. The Piramal Pharma buy or sell decision depends on your confidence that the narrowing loss trend will continue toward full profitability.
The case for buying: Investors who believe in the long-term value of Piramal Pharma’s CDMO capabilities and consumer healthcare brands, and who see the narrowing losses as evidence of a genuine turnaround, may find the stock’s proximity to its highs justified.
The case for holding: Existing shareholders who already track Piramal Pharma’s diversified business segments may prefer to stay invested and watch for continued loss narrowing.
The case for trimming or waiting: Investors who prefer companies with demonstrated, sustained profitability, rather than one still working through losses, may prefer to wait for clearer evidence of a full turnaround.
This remains a turnaround-dependent stock given the ongoing losses, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.
Conclusion
Piramal Pharma share price reflects a diversified pharmaceutical company with narrowing losses and continued revenue growth in Q1 FY27, though the business has not yet returned to full profitability after a loss-making FY26. Whether that makes the stock a buy, a hold or a sell right now depends on your confidence that this improving trajectory continues. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Piramal Pharma a good stock to buy right now?
Ans. Piramal Pharma’s Q1 FY27 net loss narrowed to Rs 69.39 crore from Rs 81.7 crore a year earlier, alongside 18.4 percent revenue growth, though the company remains loss-making overall following a loss-making FY26. This suits investors who believe in a continuing turnaround rather than those seeking demonstrated profitability.
Q2. Is Piramal Pharma profitable?
Ans. No, Piramal Pharma reported a net loss of Rs 69.39 crore in Q1 FY27, though this was narrower than the Rs 81.7 crore loss a year earlier, and the company also posted a net loss of Rs 325.94 crore for the full year FY26, a reversal from a profit in FY25.
Q3. What is the Piramal Pharma share price today?
Ans. Piramal Pharma share price is trading around Rs 213 on the NSE, close to its 52-week high of Rs 220.36. The stock’s 52-week low is Rs 132.30.
Q4. What is the Piramal Pharma share price target?
Ans. Given Piramal Pharma’s continued net losses, conventional analyst price targets are not meaningful for this stock. Investors can check the Univest Screener for the latest disclosures and should consult a SEBI-registered adviser given the elevated uncertainty involved.
Q5. What businesses does Piramal Pharma operate?
Ans. Piramal Pharma operates across contract development and manufacturing (CDMO) services for global pharmaceutical clients, complex hospital generics including inhalation anaesthesia and injectables, and an India consumer healthcare business selling over-the-counter wellness products.
Q6. What is Piramal Pharma’s market capitalisation?
Ans. Piramal Pharma has a market capitalisation of approximately Rs 28,444 crore. Given the company’s continued net losses, standard valuation ratios like PE are not meaningful indicators for this stock at this time.
